CY1107467T1 - Χρηση οξεογονων υδρογονοτροφων στελεχων για την προληψη ή την αγωγη πεπτικων διαταραχων - Google Patents
Χρηση οξεογονων υδρογονοτροφων στελεχων για την προληψη ή την αγωγη πεπτικων διαταραχωνInfo
- Publication number
- CY1107467T1 CY1107467T1 CY20061100815T CY061100815T CY1107467T1 CY 1107467 T1 CY1107467 T1 CY 1107467T1 CY 20061100815 T CY20061100815 T CY 20061100815T CY 061100815 T CY061100815 T CY 061100815T CY 1107467 T1 CY1107467 T1 CY 1107467T1
- Authority
- CY
- Cyprus
- Prior art keywords
- oxogenous
- hydro
- prevention
- treatment
- digestive disorders
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/742—Spore-forming bacteria, e.g. Bacillus coagulans, Bacillus subtilis, clostridium or Lactobacillus sporogenes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S435/00—Chemistry: molecular biology and microbiology
- Y10S435/8215—Microorganisms
- Y10S435/822—Microorganisms using bacteria or actinomycetales
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Jellies, Jams, And Syrups (AREA)
- Treatments Of Macromolecular Shaped Articles (AREA)
Abstract
Η εφεύρεση αφορά τη χρήση μη παθογόνων βακτηριακών οξεογόνων υδρογονοτρόφων στελεχών για την παρασκευή μίας συνθέσεως προοριζόμενης για την αγωγή ή την πρόληψη των γαστρεντερικών διαταραχών των σχετιζόμενων με την παραγωγή πεπτικών αερίων και/ή για τη ρύθμιση της μικροβιακής ισορροπίας του πεπτικού οικοσυστήματος στα θηλαστικά. Η εφεύρεση αφορά επίσης τις εv λόγω φαρμακευτικές ή διατροφικές συνθέσεις, καθώς και μεθόδους παρακολουθήσεως και παρασκευής των εν λόγω στελεχών.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR0006009A FR2808689B1 (fr) | 2000-05-11 | 2000-05-11 | Utilisation de souches acetogenes hydrogenotrophes pour la prevention ou le traitement de troubles digestifs |
EP01934089A EP1280541B2 (fr) | 2000-05-11 | 2001-05-11 | Utilisation de souches acetogenes hydrogenotrophes pour la prevention ou le traitement du syndrome de l'intestin irritable |
Publications (1)
Publication Number | Publication Date |
---|---|
CY1107467T1 true CY1107467T1 (el) | 2012-12-19 |
Family
ID=8850107
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CY20061100815T CY1107467T1 (el) | 2000-05-11 | 2006-06-19 | Χρηση οξεογονων υδρογονοτροφων στελεχων για την προληψη ή την αγωγη πεπτικων διαταραχων |
Country Status (13)
Country | Link |
---|---|
US (2) | US7749494B2 (el) |
EP (1) | EP1280541B2 (el) |
JP (1) | JP5183848B2 (el) |
AT (1) | ATE322902T1 (el) |
AU (2) | AU6040001A (el) |
CA (1) | CA2411563C (el) |
CY (1) | CY1107467T1 (el) |
DE (1) | DE60118723T3 (el) |
DK (1) | DK1280541T4 (el) |
ES (1) | ES2262650T5 (el) |
FR (1) | FR2808689B1 (el) |
PT (1) | PT1280541E (el) |
WO (1) | WO2001085187A1 (el) |
Families Citing this family (77)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AUPQ899700A0 (en) | 2000-07-25 | 2000-08-17 | Borody, Thomas Julius | Probiotic recolonisation therapy |
JP4618970B2 (ja) * | 2002-08-02 | 2011-01-26 | マルホ株式会社 | 肛門圧低下外用剤 |
US7935334B2 (en) * | 2005-07-07 | 2011-05-03 | Imagilin Technologies, LLC | Probiotics as alternative medicines against infectious diseases |
US20060008511A1 (en) * | 2004-07-08 | 2006-01-12 | Jhy-Jhu Lin | Probiotic products for pet applications |
DE102006062250A1 (de) * | 2006-12-22 | 2008-06-26 | Roland Saur-Brosch | Verwendung einer Zusammensetzung aus Mineralstoffen und/oder Vitaminen und gegebenenfalls acetogenen und/oder butyrogenen Bakterien zur oralen oder rektalen Verabreichung für die Behandlung und Vorbeugung von abdominalen Beschwerden |
ES2395838T3 (es) | 2007-12-21 | 2013-02-15 | Compagnie Gervais Danone | Método para disminuir el contorno abdominal administrando una bacteria del tipo Bifidobacterium |
EP2130543A1 (en) | 2008-06-05 | 2009-12-09 | Compagnie Gervais Danone | Method for decreasing borborygmi by administering a bifidobacterium bacteria |
ES2730828T3 (es) | 2010-02-01 | 2019-11-12 | Rebiotix Inc | Bacterioterapia para la colitis por Clostridium difficile |
WO2011151941A1 (ja) | 2010-06-04 | 2011-12-08 | 国立大学法人東京大学 | 制御性t細胞の増殖または集積を誘導する作用を有する組成物 |
NZ618935A (en) | 2010-08-04 | 2014-03-28 | Karma Medical Prod Co Ltd | Compositions for fecal floral transplantation and methods for making and using them and devices for delivering them |
HK1253538A1 (zh) * | 2010-08-04 | 2019-06-21 | Borody Thomas J | 用於糞便菌群植入的組合物及其製備和使用方法 |
KR101805873B1 (ko) * | 2011-08-03 | 2018-01-10 | 한화케미칼 주식회사 | 단당류 인산 또는 그 유도체로 표면이 개질된 친수성 나노입자, 그의 콜로이드 용액 및 그 용도 |
BR112013022927A2 (pt) | 2011-03-09 | 2016-12-06 | Univ Minnesota | composição, métodos para substituir ou suplementar ou modificar uma microbiota do cólon de um sujeito, e para tratar um sujeito, e, uso de uma composição |
GB201112091D0 (en) | 2011-07-14 | 2011-08-31 | Gt Biolog Ltd | Bacterial strains isolated from pigs |
GB201117313D0 (en) | 2011-10-07 | 2011-11-16 | Gt Biolog Ltd | Bacterium for use in medicine |
EP3978598B1 (en) | 2011-12-01 | 2024-08-28 | The University of Tokyo | Human-derived bacteria that induce proliferation or accumulation of regulatory t cells |
BR112014024159A2 (pt) | 2012-03-29 | 2017-06-20 | Therabiome Llc | Formulações de vacina oral específicas do local gastrintestinal , ativas no íleo e apêndice. |
WO2013176774A1 (en) | 2012-05-25 | 2013-11-28 | Arizona Board Of Regents | Microbiome markers and therapies for autism spectrum disorders |
US9907755B2 (en) | 2013-03-14 | 2018-03-06 | Therabiome, Llc | Targeted gastrointestinal tract delivery of probiotic organisms and/or therapeutic agents |
GB201306536D0 (en) | 2013-04-10 | 2013-05-22 | Gt Biolog Ltd | Polypeptide and immune modulation |
US9511099B2 (en) | 2013-06-05 | 2016-12-06 | Rebiotix, Inc. | Microbiota restoration therapy (MRT), compositions and methods of manufacture |
WO2014197562A1 (en) | 2013-06-05 | 2014-12-11 | Rebiotix, Inc. | Microbiota restoration therapy (mrt), compositions and methods of manufacture |
US9782445B2 (en) | 2013-06-05 | 2017-10-10 | Rebiotix, Inc. | Microbiota restoration therapy (MRT), compositions and methods of manufacture |
US10383901B2 (en) | 2013-06-05 | 2019-08-20 | Rebiotix, Inc. | Microbiota restoration therapy (MRT), compositions and methods of manufacture |
US9511100B2 (en) | 2013-06-05 | 2016-12-06 | Rebiotix, Inc. | Microbiota restoration therapy (MRT), compositions and methods of manufacture |
US9694039B2 (en) | 2013-06-05 | 2017-07-04 | Rebiotix, Inc. | Microbiota restoration therapy (MRT), compositions and methods of manufacture |
MA41020A (fr) | 2014-11-25 | 2017-10-03 | Evelo Biosciences Inc | Compositions probiotiques et prébiotiques, et leurs procédés d'utilisation pour la modulation du microbiome |
SI3065748T1 (en) | 2014-12-23 | 2018-05-31 | 4D Pharma Research Limited | Severe bacteroid tethethioomycron and its use in reducing inflammation |
JP6427278B2 (ja) | 2014-12-23 | 2018-11-21 | フォーディー ファーマ リサーチ リミテッド4D Pharma Research Limited | pirinポリペプチド及び免疫モジュレーション |
CA2977593A1 (en) | 2015-02-27 | 2016-09-01 | White Dog Labs, Inc. | Mixotrophic fermentation method for making acetone, isopropanol, butyric acid and other bioproducts, and mixtures thereof |
CN114990099A (zh) | 2015-05-11 | 2022-09-02 | 迈彼欧提克斯制药有限公司 | 用于使益生菌在使细菌于肠道中定植用途的固体颗粒上生长成益生菌生物膜的系统和方法 |
WO2016183577A1 (en) | 2015-05-14 | 2016-11-17 | Crestovo Llc | Compositions for fecal floral transplantation and methods for making and using them and devices for delivering them |
ES2909456T3 (es) | 2015-05-22 | 2022-05-06 | Univ Arizona State | Métodos para tratar el trastorno del espectro autista y síntomas asociados |
WO2016201114A1 (en) | 2015-06-09 | 2016-12-15 | Rebiotix, Inc. | Microbiota restoration therapy (mrt) compositions and methods of manufacture |
US10828340B2 (en) | 2015-06-09 | 2020-11-10 | Rebiotix, Inc. | Microbiota restoration therapy (MRT) compositions and methods of manufacture |
US10905726B2 (en) | 2015-06-09 | 2021-02-02 | Rebiotix, Inc. | Microbiota restoration therapy (MRT) compositions and methods of manufacture |
US10799539B2 (en) | 2015-06-09 | 2020-10-13 | Rebiotix, Inc. | Microbiota restoration therapy (MRT) compositions and methods of manufacture |
SI3360559T1 (sl) | 2015-06-15 | 2020-02-28 | 4D Pharma Research Limited | Sestavki, ki vsebujejo bakterijske seve |
MA41060B1 (fr) | 2015-06-15 | 2019-11-29 | 4D Pharma Res Ltd | Compositions comprenant des souches bactériennes |
MA41010B1 (fr) | 2015-06-15 | 2020-01-31 | 4D Pharma Res Ltd | Compositions comprenant des souches bactériennes |
CN114984057A (zh) | 2015-06-15 | 2022-09-02 | 4D制药研究有限公司 | 包含细菌菌株的组合物 |
RS59446B1 (sr) | 2015-06-15 | 2019-11-29 | 4D Pharma Res Ltd | Blautia stercosis i wexlerae za upotrebu u lečenju inflamatornih i autoimunskih bolesti |
GB201520497D0 (en) | 2015-11-20 | 2016-01-06 | 4D Pharma Res Ltd | Compositions comprising bacterial strains |
EP3209310B1 (en) | 2015-11-20 | 2018-01-31 | 4D Pharma Research Limited | Compositions comprising bacterial strains |
GB201520638D0 (en) | 2015-11-23 | 2016-01-06 | 4D Pharma Res Ltd | Compositions comprising bacterial strains |
GB201520631D0 (en) | 2015-11-23 | 2016-01-06 | 4D Pharma Res Ltd | Compositions comprising bacterial strains |
NZ745678A (en) | 2016-03-04 | 2019-03-29 | 4D Pharma Plc | Compositions comprising bacterial blautia strains for treating visceral hypersensitivity |
GB201612191D0 (en) | 2016-07-13 | 2016-08-24 | 4D Pharma Plc | Compositions comprising bacterial strains |
JP7198087B2 (ja) | 2016-05-25 | 2022-12-28 | マイバイオティクス ファーマ リミテッド | 微生物叢療法のための組成物及び方法 |
US20170360848A1 (en) | 2016-06-15 | 2017-12-21 | Arizona Board Of Regents On Behalf Of Arizona State University | Methods for treating autism spectrum disorder and associated symptoms |
US10849936B2 (en) | 2016-07-01 | 2020-12-01 | Regents Of The University Of Minnesota | Compositions and methods for C. difficile treatment |
GB201703548D0 (en) * | 2017-03-06 | 2017-04-19 | 4D Pharma Plc | Compositions comprising bacterial strains |
TW201821093A (zh) | 2016-07-13 | 2018-06-16 | 英商4D製藥有限公司 | 包含細菌菌株之組合物 |
GB201703552D0 (en) * | 2017-03-06 | 2017-04-19 | 4D Pharma Plc | Compositions comprising bacterial strains |
US20180036352A1 (en) | 2016-08-03 | 2018-02-08 | Crestovo Holdings Llc | Methods for treating ulcerative colitis |
US11213549B2 (en) | 2016-10-11 | 2022-01-04 | Finch Therapeutics Holdings Llc | Compositions and method for treating primary sclerosing cholangitis and related disorders |
US10092601B2 (en) | 2016-10-11 | 2018-10-09 | Crestovo Holdings Llc | Compositions and methods for treating multiple sclerosis and related disorders |
US11026978B2 (en) | 2016-10-11 | 2021-06-08 | Finch Therapeutics Holdings Llc | Compositions and methods for treating multiple sclerosis and related disorders |
GB201621123D0 (en) * | 2016-12-12 | 2017-01-25 | 4D Pharma Plc | Compositions comprising bacterial strains |
WO2018187464A1 (en) | 2017-04-05 | 2018-10-11 | Crestovo Holdings Llc | Compositions and methods for treating diverticulitis and related disorders |
US11433102B2 (en) | 2017-04-05 | 2022-09-06 | Finch Therapeutics Holdings Llc | Compositions and methods for treating Parkinson's disease (PD) and related disorders |
AU2018272291A1 (en) * | 2017-05-22 | 2020-01-16 | 4D Pharma Research Limited | Compositions comprising bacterial strains |
TW201907931A (zh) | 2017-05-24 | 2019-03-01 | 英商4D製藥研究有限公司 | 包含細菌菌株之組合物 |
JP2020521760A (ja) | 2017-05-26 | 2020-07-27 | クレストヴォ・ホールディングス・エルエルシー | 糞便微生物ベースの治療剤を含む凍結乾燥組成物ならびにそれを製造および使用する方法 |
HUE052319T2 (hu) | 2017-06-14 | 2021-04-28 | 4D Pharma Res Ltd | Baktériumtörzseket tartalmazó készítmények |
CN111107859B (zh) | 2017-06-14 | 2022-04-29 | 4D制药研究有限公司 | 包含细菌菌株的组合物 |
ES2917415T3 (es) | 2017-06-14 | 2022-07-08 | 4D Pharma Res Ltd | Composiciones que comprenden una cepa bacteriana |
CN111328284A (zh) | 2017-08-07 | 2020-06-23 | 芬奇治疗公司 | 用于维持和恢复健康的肠道屏障的组合物和方法 |
TW202007400A (zh) | 2018-06-19 | 2020-02-16 | 英商4D製藥研究有限公司 | 產品 |
US11166990B2 (en) | 2018-07-13 | 2021-11-09 | Finch Therapeutics Holdings Llc | Methods and compositions for treating ulcerative colitis |
WO2020016252A1 (en) | 2018-07-16 | 2020-01-23 | 4D Pharma Research Limited | Compositions comprising bacterial strains |
US11911419B2 (en) | 2018-09-27 | 2024-02-27 | Finch Therapeutics Holdings Llc | Compositions and methods for treating epilepsy and related disorders |
TW202108153A (zh) | 2019-05-10 | 2021-03-01 | 英商4D製藥研究有限公司 | 包含細菌菌株之組成物 |
US20220331376A1 (en) * | 2019-09-05 | 2022-10-20 | White Dog Labs | Mixotrophic probiotic compositions and uses thereof in the treatment of bloating |
EP3839039A1 (en) | 2019-12-16 | 2021-06-23 | 4D Pharma Research Limited | Providing bacterial biomass with improved storage stability |
TW202220639A (zh) | 2020-08-06 | 2022-06-01 | 英商4D製藥有限公司 | 凍乾方法 |
WO2022112526A1 (en) | 2020-11-26 | 2022-06-02 | 4D Pharma Leon, S.L.U. | Process |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5443826A (en) * | 1988-08-02 | 1995-08-22 | Borody; Thomas J. | Treatment of gastro-intestinal disorders with a fecal composition or a composition of bacteroides and E. Coli |
AUPM823094A0 (en) | 1994-09-16 | 1994-10-13 | Goodman Fielder Limited | Probiotic compositions |
AUPM864894A0 (en) * | 1994-10-07 | 1994-11-03 | Borody, Thomas Julius | Treatment of bowel-dependent neurological disorders |
AUPN698495A0 (en) * | 1995-12-06 | 1996-01-04 | Pharma Pacific Pty Ltd | Improved therapeutic formulation and method |
WO1997034591A1 (en) * | 1996-03-20 | 1997-09-25 | The University Of New South Wales | Alteration of microbial populations in the gastrointestinal tract |
SE511524C2 (sv) | 1997-06-02 | 1999-10-11 | Essum Ab | Lactobacillus casei rhamnosus-stam samt farmaceutisk beredning för bekämpning av patogena tarmbakterier |
DE19826928A1 (de) † | 1998-06-17 | 1999-12-23 | Novartis Consumer Health Gmbh | Arzneimittel, lebensfähige anaerobe Bakterien enthaltend, die die Sulfatreduktion sulfatreduzierender Bakterien hemmen |
WO2000010581A1 (fr) * | 1998-08-20 | 2000-03-02 | Miyarisan Pharmaceutical Co., Ltd. | Medicaments comprenant une combinaison d'une bacterie produisant de l'acide butyrique, et d'un constituant d'acide biliaire |
-
2000
- 2000-05-11 FR FR0006009A patent/FR2808689B1/fr not_active Expired - Lifetime
-
2001
- 2001-05-11 AT AT01934089T patent/ATE322902T1/de active
- 2001-05-11 WO PCT/FR2001/001426 patent/WO2001085187A1/fr active IP Right Grant
- 2001-05-11 CA CA2411563A patent/CA2411563C/fr not_active Expired - Lifetime
- 2001-05-11 JP JP2001581840A patent/JP5183848B2/ja not_active Expired - Lifetime
- 2001-05-11 DK DK01934089.2T patent/DK1280541T4/da active
- 2001-05-11 EP EP01934089A patent/EP1280541B2/fr not_active Expired - Lifetime
- 2001-05-11 AU AU6040001A patent/AU6040001A/xx active Pending
- 2001-05-11 US US10/275,706 patent/US7749494B2/en not_active Expired - Lifetime
- 2001-05-11 AU AU2001260400A patent/AU2001260400B2/en not_active Expired
- 2001-05-11 DE DE60118723T patent/DE60118723T3/de not_active Expired - Lifetime
- 2001-05-11 PT PT01934089T patent/PT1280541E/pt unknown
- 2001-05-11 ES ES01934089T patent/ES2262650T5/es not_active Expired - Lifetime
-
2006
- 2006-06-19 CY CY20061100815T patent/CY1107467T1/el unknown
-
2010
- 2010-04-15 US US12/760,926 patent/US20100316617A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
DE60118723D1 (de) | 2006-05-24 |
ATE322902T1 (de) | 2006-04-15 |
AU2001260400B2 (en) | 2006-10-26 |
JP5183848B2 (ja) | 2013-04-17 |
FR2808689A1 (fr) | 2001-11-16 |
DE60118723T2 (de) | 2006-12-28 |
JP2004501095A (ja) | 2004-01-15 |
CA2411563A1 (fr) | 2001-11-15 |
US20030147858A1 (en) | 2003-08-07 |
WO2001085187A1 (fr) | 2001-11-15 |
PT1280541E (pt) | 2006-06-30 |
CA2411563C (fr) | 2012-12-11 |
EP1280541B1 (fr) | 2006-04-12 |
EP1280541B2 (fr) | 2010-03-17 |
US7749494B2 (en) | 2010-07-06 |
DK1280541T3 (da) | 2006-07-17 |
EP1280541A1 (fr) | 2003-02-05 |
FR2808689B1 (fr) | 2004-09-03 |
AU6040001A (en) | 2001-11-20 |
DE60118723T3 (de) | 2010-09-30 |
ES2262650T3 (es) | 2006-12-01 |
US20100316617A1 (en) | 2010-12-16 |
DK1280541T4 (da) | 2010-07-05 |
ES2262650T5 (es) | 2010-06-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CY1107467T1 (el) | Χρηση οξεογονων υδρογονοτροφων στελεχων για την προληψη ή την αγωγη πεπτικων διαταραχων | |
DK1539166T3 (da) | Farmaceutiske sammensætninger indeholdende dextromethorphan og quinidin til behandling af neurologiske sygdomme | |
NO20061736L (no) | Krystallform av epotilon B | |
DK1781277T3 (da) | Kombinationssammensætning, der omfatter Ibuprofen og Paracetamol | |
TR199901417T2 (xx) | Analjezik etkisi olan yeni bile�imler. | |
ATE413386T1 (de) | Ppar-gamma modulatoren | |
DK1169060T3 (da) | Natriumkanalblokkerpræparater og anvendelse deraf | |
DK0839026T3 (da) | Micellære polyether-blokcopolymerkompositioner til målretning af biologiske midler | |
BR0015992A (pt) | Compostos, utilização dos mesmos, e, associações terapêuticas | |
BRPI0411319A (pt) | compostos terapeuticamente ativos e sua utilização | |
CY1114133T1 (el) | ΥΠΟΚΑΤΕΣΤΗΜΕΝΕΣ γ-ΦΑΙΝΥΛ-Δ-ΛΑΚΤΑΜΕΣ ΚΑΙ ΧΡΗΣΕΙΣ ΠΟΥ ΣΧΕΤΙΖΟΝΤΑΙ ΠΡΟΣ ΑΥΤΕΣ | |
ATE364595T1 (de) | Pyridoxin- und pyridoxalanaloga als cardiovasculäre therapeutika | |
ATE506959T1 (de) | Verwendung von il-18 inhibitoren | |
NO20054668L (no) | Aplidin for multippelt myelom-behandling | |
DE60142913D1 (de) | Arzneilösungen enthaltend modafinilverbindungen | |
RS49599B (sr) | Upotreba inhibitora h+, k+-atp-aze i glukokortikoida i farmaceutska formulacija | |
DK1294379T3 (da) | En hidtil ukendt anvendelse af deferipron | |
ATE405294T1 (de) | Gezielt eingesetzte agenzien zur nervenregeneration | |
DE60229867D1 (de) | Zielgerichtete ligande gegen peyer's flecke- und/oder m-zellen | |
MXPA02012911A (es) | Compuestos de rutenio (ii) para el uso en terapia del cancer. | |
DK1596879T3 (da) | Anvendelse af kahalalidforbindelser til fremstilling af et medikament til behandling af psoriasis | |
DK1052991T3 (da) | Topisk anvendelse af loperamid til behandling af mikrobielle infektioner | |
DK1212072T3 (da) | Farmaceutisk præparat omfattende eukalyptus- og orangeolie | |
ATE241640T1 (de) | Fusidinsäure-derivate | |
EP1370697A4 (en) | PEROXYREDOXIN-BASED MEDICINAL PRODUCTS FOR THE TREATMENT OF HIV-1 INFECTIONS AND METHODS OF USE |